Keyphrases
Monoclonal Antibody
100%
Cancer Immunotherapy
100%
IUPHAR
100%
Oligoclonal Bands
100%
Anti-cancer Antibody
100%
Hetero
50%
T Cells
25%
Tumor
25%
Cancer Cells
25%
Pharmacology
25%
Clinical Application
25%
Human Epidermal Growth Factor Receptor 2 (HER2)
25%
Clinical Trials
25%
Evade
25%
Receptor Tyrosine Kinase
25%
Induced Cell Death
25%
Clinical Efficacy
25%
Synergistic Antitumor Effect
25%
Transient Response
25%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
25%
Melanoma Treatment
25%
Residual Fraction
25%
Oncologic
25%
Breast Cancer Treatment
25%
Partial Response
25%
Soluble Ligand
25%
T-cell Antigen
25%
Clinical Testing
25%
Oligoclonal Antibodies
25%
Kinase Inhibitor
25%
Antibody Mixtures
25%
Membrane Antigens
25%
Antibody Therapy
25%
Tumor Resistance
25%
Antibody Cocktail
25%
Medicine and Dentistry
Malignant Neoplasm
100%
Immunotherapy
100%
Monoclonal Antibody
100%
Cancer Antibody
100%
Neoplasm
50%
Breast Cancer
25%
Cancer Cell
25%
Clinical Trial
25%
Protein Tyrosine Kinase
25%
Cell Death
25%
Phosphotransferase Inhibitor
25%
T Lymphocyte
25%
Membrane Antigen
25%
T Lymphocyte Antigen
25%
Tumor Resistance
25%
Aminomethyltransferase
25%
Melanoma
25%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Monoclonal Antibody
100%
Malignant Neoplasm
100%
Cancer Antibody
100%
Neoplasm
50%
Membrane Antigen
25%
Protein Tyrosine Kinase
25%
Breast Cancer
25%
Clinical Trial
25%
Melanoma
25%
Phosphotransferase Inhibitor
25%
Tumor Resistance
25%
T Lymphocyte Antigen
25%
Cytotoxic T Lymphocyte Antigen 4
25%
Immunology and Microbiology
Immunotherapy
100%
Cancer Antibody
100%
Immunology
100%
Monoclonal Antibody
66%
T Cell
16%
Cancer Cell
16%
Cell Death
16%
T Lymphocyte Antigen
16%
Membrane Antigen
16%
Vein
16%